| Revision as of 23:01, 13 December 2024 editWhywhenwhohow (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers49,153 edits create | Latest revision as of 05:06, 23 December 2024 edit undoWhywhenwhohow (talk | contribs)Autopatrolled, Extended confirmed users, Pending changes reviewers49,153 edits infobox | ||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 12: | Line 12: | ||
| <!-- Monoclonal antibody data --> | <!-- Monoclonal antibody data --> | ||
| | mab_type = mab | | mab_type = mab | ||
| | source = | | source = u | ||
| | target = | | target = ] | ||
| <!-- Clinical data --> | <!-- Clinical data --> | ||
| Line 26: | Line 26: | ||
| | routes_of_administration = | | routes_of_administration = | ||
| | class = Bleeding suppressant | | class = Bleeding suppressant | ||
| | ATC_prefix = |
| ATC_prefix = B06 | ||
| | ATC_suffix = | | ATC_suffix = AC07 | ||
| | ATC_supplemental = | | ATC_supplemental = | ||
| | biosimilars = | | biosimilars = | ||
| Line 67: | Line 67: | ||
| | PubChem = | | PubChem = | ||
| | IUPHAR_ligand = | | IUPHAR_ligand = | ||
| | DrugBank = | | DrugBank = DB15629 | ||
| | ChemSpiderID = | | ChemSpiderID = | ||
| | UNII = 32W6AJL0DY | | UNII = 32W6AJL0DY | ||
| Line 75: | Line 75: | ||
| | NIAID_ChemDB = | | NIAID_ChemDB = | ||
| | PDB_ligand = | | PDB_ligand = | ||
| | synonyms = | | synonyms = CSL-312 | ||
| <!-- Chemical and physical data --> | <!-- Chemical and physical data --> | ||
| Line 101: | Line 101: | ||
| }} | }} | ||
| '''Garadacimab''' is an experimental ] under investigation for the treatment of ].<ref name="Andembry EPAR" /> Garadacimab is a |
'''Garadacimab''' is an experimental ] under investigation for the treatment of ].<ref name="Andembry EPAR" /> Garadacimab is a monoclonal antibody against the activated coagulation factor XIIa (FXIIa), with potential anti-inflammatory and anticoagulant activities.<ref>{{cite web | title=Garadacimab (Code C166633) | website=NCI Thesaurus | date=25 November 2024 | url=https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C166633 | access-date=13 December 2024}} {{PD-notice}}</ref><ref name="Cohn_2024">{{cite journal | vauthors = Cohn DM, Renné T | title = Targeting factor XIIa for therapeutic interference with hereditary angioedema | journal = Journal of Internal Medicine | volume = 296 | issue = 4 | pages = 311–326 | date = October 2024 | pmid = 39331688 | doi = 10.1111/joim.20008 | doi-access = free | title-link = doi }}</ref> | ||
| Garadacimab is a fully human, recombinant, IgG4 lambda monoclonal antibody that binds to the catalytic domain of activated factor XII (FXIIa).<ref name="Andembry EPAR" /> FXIIa is the first factor activated in the contact system, which leads to the production of bradykinin.<ref name="Andembry EPAR" /> The inhibition of FXIIa therefore prevents the activation of prekallikrein into kallikrein and the generation of bradykinin, which is associated with inflammation and swelling in attacks of hereditary angioedema.<ref name="Andembry EPAR" /> | |||
| == Society and culture == | == Society and culture == | ||
| Line 116: | Line 118: | ||
| {{Other hematological agents}} | {{Other hematological agents}} | ||
| {{Monoclonals for immune system}} | |||
| {{Portal bar | Medicine}} | {{Portal bar | Medicine}} | ||
| {{Authority control}} | {{Authority control}} | ||
| ] | |||
| ] | |||
| ] | ] | ||
Latest revision as of 05:06, 23 December 2024
MedicationPharmaceutical compound
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | Coagulation factor XIIa |
| Clinical data | |
| Other names | CSL-312 |
| Drug class | Bleeding suppressant |
| ATC code | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
Garadacimab is an experimental human monoclonal antibody under investigation for the treatment of hereditary angioedema. Garadacimab is a monoclonal antibody against the activated coagulation factor XIIa (FXIIa), with potential anti-inflammatory and anticoagulant activities.
Garadacimab is a fully human, recombinant, IgG4 lambda monoclonal antibody that binds to the catalytic domain of activated factor XII (FXIIa). FXIIa is the first factor activated in the contact system, which leads to the production of bradykinin. The inhibition of FXIIa therefore prevents the activation of prekallikrein into kallikrein and the generation of bradykinin, which is associated with inflammation and swelling in attacks of hereditary angioedema.
Society and culture
Legal status
In December 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Andembry, intended for the prevention of recurrent attacks of hereditary angioedema. The applicant for this medicinal product is CSL Behring GmbH.
Garadacimab was designated an orphan medicine by the EMA.
Names
Garadacimab is the international nonproprietary name.
References
- ^ "Andembry EPAR". European Medicines Agency (EMA). 12 December 2024. Retrieved 13 December 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- "Garadacimab (Code C166633)". NCI Thesaurus. 25 November 2024. Retrieved 13 December 2024.
This article incorporates text from this source, which is in the public domain.
- Cohn DM, Renné T (October 2024). "Targeting factor XIIa for therapeutic interference with hereditary angioedema". Journal of Internal Medicine. 296 (4): 311–326. doi:10.1111/joim.20008. PMID 39331688.
- World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information. 33 (3). hdl:10665/330879.
| Other hematological agents (B06) | |
|---|---|
| Enzymes (B06AA) | |
| Drugs used in hereditary angioedema (B06AC) | |
| Drugs used in sickle cell disease and beta thalassemia (B06AX) | |
| Others | |
 | This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it. |